Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof

A monoclonal antibody, PD-1 technology, applied in the direction of antibody, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antiviral agent, etc., to achieve the effect of promoting secretion, high affinity and wide application prospect

Inactive Publication Date: 2013-08-14
ZHENGZHOU UNIV
View PDF4 Cites 75 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These results confirm that blocking PD-1 signaling may be applied to the clinical treatment of viral infections such as HIV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof
  • Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof
  • Full-humanized anti-PD-1 monoclonal antibody and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] The present invention will be further described below in conjunction with specific examples and test examples, but it should not be understood as a limitation of the present invention.

[0028] 1. Preparation of cDNA

[0029] Collect 10 ml of peripheral blood from 50 people with liver cancer, kidney cancer, melanoma, and healthy people, anticoagulate with heparin sodium, separate mononuclear cells (PBMC) by density gradient centrifugation, and use PD-1 antigen for in vitro sensitization. After PBMC were sensitized in vitro, press 4×10 6 Add 1ml of EBV culture supernatant to PBMC, incubate at 37°C for 3 hours, discard the supernatant, add RPMI 1640 complete medium containing 100ml / L FCS, culture for 2 weeks, replace with RPMI 1640 complete medium containing 200ml / L NBS . The culture supernatant of transformed cells was screened by indirect ELISA method, using PD-1 as the tumor cell antigen solid phase plate, the collected B cell culture supernatant as the primary antib...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a full-humanized anti-PD-1 monoclonal antibody having a heavy-chain amino acid sequence shown in a sequence 7 in a sequence table and a light-chain amino acid sequence shown in a sequence 8 in the sequence table. The full-humanized anti-PD-1 monoclonal antibody has the advantages that the antibody has high appetency and low immunogenicity on PD-1, is efficiently expressed in animal cells, and can be used for industrial production. An experiment proves that the full-humanized anti-PD-1 monoclonal antibody specifically blocks a PD-1 / PD-L inhibiting signal, so that a disabled effector cell in an organism restores a biological function; activation proliferation of a tumor and a virus specificity CD8+T cell and secretion of a cell factor are facilitated; the killability of lymphocyte on tumor antigen, an exotic invasive virus and the like is enhanced; the immunity of the organism is improved; and the tumor cell and the virus are timely cleared. Therefore, the antibody disclosed by the invention has a wide application prospect on treatment of tumors, infectious diseases and autoimmune diseases.

Description

technical field [0001] The invention relates to the field of development and production of antibodies and antibody drugs, in particular to the acquisition of a fully humanized monoclonal antibody against human PD-1, and also relates to a preparation method and application of the monoclonal antibody. Background technique [0002] PD-1 (CD279) is an immunoglobulin superfamily type I transmembrane glycoprotein composed of 288 amino acids, which was originally cloned from the apoptotic mouse T cell hybridoma 2B4. Named programmed death-1 (programmed death-1, PD-1). When initially discovered, PD-1 was recognized as a member of the CD28 superfamily because of its structural resemblance to the CD28 molecule. However, PD-1 protein lacks the MYPPPY sequence that mediates the combination of CD28 / CTLA-4 and B7.1 / B7.2, and the FDPPPF sequence that mediates the combination of ICOS and ICOS-L, so it is structurally related to CD28, CTLA -4 and ICOS are significantly different. Therefo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C12N15/85A61K39/395A61P31/12A61P35/00A61P37/02
Inventor 方惠敏张守涛张一折
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com